Device and Methods
AssigneeEpona Biotech Ltd
InventorsHeinrich Anhold, Ruth Candon, Di-Sien Chan
Life of this patent
Estimating the term…
Abstract
There is provided a method and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. Diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy are provided. A test fluid collection system adapted to permit dilution and analysis of the collected test fluid and an assay and device for monitoring exertional rhabdomyolysis in equines is also provided.
Claims17
A method of predicting whether a mammal exhibiting an abnormal symptom or behaviour will have an improved benefit from administration of an anti-infective, a period of rest, or a combination thereof, the method comprising:
- determining whether a body fluid sample obtained from the mammal has a concentration of Serum Amyloid A above about 15 μg/ml;
- and
- predicting the mammal to have an improved benefit from administration of an anti-infective, a period of rest, or a combination thereof based on the concentration of Serum Amyloid A being above about 15 μg/ml, the concentration indicating that the abnormal symptom or behaviour results from an infectious disease.
A portable lateral flow device comprising:
- (i) a housing;
- and
- (ii) a flow path leading from a sample well to a viewing window, through which the body fluid sample can flow by capillary action, wherein the presence of Serum Amyloid A produces a line in the viewing window which indicates a Serum Amyloid A concentration of at or above 15 μg/ml in a body fluid sample, and wherein the device measures a Serum Amyloid A concentration over at least the range of 7.5 to 3000 μg/ml, and wherein the assay result within the concentration range 7.5 to 1000 μg/ml can be visually interpreted with a naked eye based on the intensity of the line, optionally by comparison to a reference showing different line intensities.
A method of monitoring disease progression in a mammal, the method comprising:
- determining whether a concentration of Serum Amyloid A in a body fluid sample of said mammal is above a specified level, wherein if the concentration of Serum Amyloid A is above the specified level it indicates that the mammal requires a treatment to treat the disease;
- administering the treatment to the mammal;
- and
- determining whether the concentration of Serum Amyloid A in a body fluid sample of said mammal is above or below the specified level following treatment,
- wherein if the concentration of Serum Amyloid A is below the specified level it indicates that the disease is responding to the treatment and the mammal is improving and the treatment can be withdrawn, or if the concentration of Serum Amyloid A is above the specified level it indicates that the disease is progressing and the treatment can be continued, wherein the treatment to the mammal comprises a period of rest for the mammal;
- and/or
- administration of an anti-infective to the mammal, and wherein said specified level is 15 μg/ml.
A method of distinguishing infectious disease from non-infectious disease in a mammal, the method comprising:
- determining whether the concentration of Serum Amyloid A in a body fluid sample of said mammal is above or below a specified level, wherein if the concentration of Serum Amyloid A is below the specified level it indicates that the presence of an infectious disease, or if the concentration of Serum Amyloid A is above the specified level it indicates the presence of a non-infectious disease;
- and wherein said specified level is 15 μg/ml;
- and
- wherein the concentration of Serum Amyloid A is determined using an analytical device and wherein the analytical device is a portable lateral flow device comprising:
- (i) a housing;
- and
- (ii) a flow path leading from a sample well to a viewing window, through which the body fluid sample can flow by capillary action, wherein the presence of Serum Amyloid A produces a line in the viewing window which indicates a Serum Amyloid A concentration of at or above 15 μg/ml in the body fluid sample, and
- wherein the device measures a Serum Amyloid A concentration over at least the range of 7.5 to 3000 μg/ml, and
- wherein the assay result within the concentration range 7.5 to 1000 μg/ml can be visually interpreted with the naked eye based on the intensity of the line, optionally by comparison to a reference showing different line intensities.
Dependencies are inferred from the claim text.